



## **(PCA) Patient Care Advocate Medication Management**

### **Disease State: Multiple Sclerosis**

#### **Medication Reconciliation**

The pharmacist will:

- Determine and document the patient's current medications (prescription and over-the-counter)
- Perform a comprehensive medication review addressing appropriateness, duplications, and any drug-drug interactions with patient's medication regimen.
- Address compliance and adherence issues with current medications and discuss the importance of being compliant with disease modifying agents.
- Review relevant findings with the patient and/or prescriber, intervene as clinically appropriate, and educate the patient as necessary.

#### **Initial Assessment (Prior to patient receiving 1st fill)**

The pharmacist will review the *appropriateness* of medication therapy:

- Ensure accurate dosing of disease modifying agents based on manufacturer's prescribing information and approved guidelines. If there are any discrepancies contact physician's office to discuss/clarify.

#### **The pharmacist will *educate* the patient on:**

- Medication's use and expected benefits
- Medication administration
- Possible side effects
- Storage and Disposal of self-administered injectable medications
- Importance of compliance
- The use of Starter Kits and also Medication Guides to complement the pharmacist's efforts with patient education. Patients will also be provided information on manufacturer programs.

#### **Subsequent Assessment**

- The pharmacist will document any compliance issues, side effects of treatment, and MS related symptoms and contact the patient's prescriber either by telephone or fax suggesting interventions based on clinical-evidence based medicine. The pharmacist will educate the patient as clinically relevant.
- Pharmacist Interventions
- The pharmacist will record ALL interventions and recommendations suggested to a patient and/or patient's physician(s) that results in a change or enhancement of patient's medication regimen.
- Informed Decision Making
- A detailed outline of the patient's rights and responsibilities is provided to the patient at the time of first fill to allow for informed decision making. Prescribers will also receive a letter via fax to inform them of their patient's enrollment in the MS monitoring program. The pharmacist will also verbally disclose the outcomes of treatment, all available treatment options and the potential harms and benefits of these options.
- Expected Outcomes
- Increase monitoring and patient education on disease modifying agents can improve medication adherence and maintain overall health-related quality of life.